UPXI UPEXI, INC.
Nasdaq · SEC CIK 1775194 · EDGAR
- Bought, last 12 months
- $1.07M 5 purchases by 2 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 42 since 2021-08-30, latest 2026-07-20 17:36
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Salkind Gene | Dir | $673.5K | — |
| MARSHALL ALLAN | CEO, Dir | $400.5K | — |
| Rudick Brian Benjamin | Chief Strategy Off | — | — |
| Dugan Lawrence | Dir | — | — |
| Norstrud Andrew James | CFO, Dir | — | — |
Transactions 38
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-20 17:36 | 2026-07-03 | UPXI | Salkind Gene | Dir | A - Grant | $0.00 | +100.0K | 318.8K | +46% | $0 | |
| 2026-07-20 17:28 | 2026-07-03 | UPXI | Dugan Lawrence | Dir | A - Grant | $0.00 | +100.0K | 216.4K | +86% | $0 | |
| 2026-07-20 17:28 | 2026-07-03 | UPXI | Rudick Brian Benjamin | Chief Strategy Off | A - Grant | $0.00 | +400.0K | 1.24M | +48% | $0 | |
| 2026-07-20 17:27 | 2026-07-03 | UPXI | MARSHALL ALLAN | CEO, Dir | A - Grant | $0.00 | +2.00M | 6.05M | +49% | $0 | |
| 2026-07-20 17:27 | 2026-07-03 | UPXI | Norstrud Andrew James | CFO, Dir | A - Grant | $0.00 | +400.0K | 1.05M | +62% | $0 | |
| 2025-12-23 | 2025-12-23 | UPXI | MARSHALL ALLAN | CEO, Dir | P - Purchase | $1.80 | +50.0K | 4.05M | +1% | +$90.0K | |
| 2025-12-17 | 2025-10-01 | UPXI | MARSHALL ALLAN | CEO, Dir | A - Grant | $0.00 | +1.60M | 3.85M | +71% | $0 | |
| M | 2025-12-17 | 2025-12-15+ | UPXI | MARSHALL ALLAN | CEO, Dir | P - Purchase | $2.07 | +150.0K | 4.00M | +4% | +$310.5K |
| I | 2025-11-21 | 2025-11-20 | UPXI | Salkind Gene | Dir | P - Purchase | $2.55 | +50.0K | 218.8K | +30% | +$127.5K |
| 2025-11-21 | 2025-10-01 | UPXI | Norstrud Andrew James | CFO, Dir | A - Grant | $0.00 | +240.0K | 649.1K | +59% | $0 | |
| I | 2025-11-18 | 2025-11-17 | UPXI | Salkind Gene | Dir | P - Purchase | $2.81 | +100.0K | 168.8K | +145% | +$281.0K |
| 2025-11-18 | 2025-11-17 | UPXI | Salkind Gene | Dir | P - Purchase | $2.65 | +100.0K | 569.5K | +21% | +$265.0K | |
| M | 2025-07-30 | 2025-07-16 | UPXI | Salkind Gene | Dir, 10% | A - Grant | $0.00 | +200.0K | 435.4K | +85% | $0 |
| 2025-07-30 | 2025-07-11 | UPXI | Salkind Gene | Dir, 10% | P - Purchase | $4.94 | +20.2K | 385.4K | +6% | +$100.0K | |
| M | 2025-07-24 | 2025-07-15+ | UPXI | Dugan Lawrence | Dir | P - Purchase | $6.11 | +16.0K | 112.4K | +17% | +$97.8K |
| M | 2025-07-24 | 2025-07-16 | UPXI | Dugan Lawrence | Dir | A - Grant | $0.00 | +100.0K | 101.4K | +7,199% | $0 |
| 2025-07-24 | 2025-07-16 | UPXI | Norstrud Andrew James | CFO, Dir | A - Grant | $0.00 | +250.0K | 409.1K | +157% | $0 | |
| 2025-07-24 | 2025-07-11 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $4.94 | +161.9K | 1.05M | +18% | +$800.0K | |
| 2025-07-24 | 2025-07-16 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | A - Grant | $0.00 | +1.20M | 2.25M | +115% | $0 | |
| M | 2025-07-24 | 2025-07-16 | UPXI | Williams Thomas Charles | Dir | A - Grant | $0.00 | +100.0K | 100.0K | New | $0 |
| 2025-07-24 | 2025-07-16 | UPXI | Rudick Brian Benjamin | CSO | A - Grant | $0.00 | +400.0K | 838.6K | +91% | $0 | |
| D | 2025-04-25 | 2025-04-17 | UPXI | Salkind Gene | Dir, 10% | P - Purchase | $2.28 | +241.2K | 365.1K | +195% | +$550.0K |
| D | 2025-04-25 | 2025-04-17 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | A - Grant | $0.00 | +75.0K | 884.3K | +9% | $0 |
| D | 2025-04-25 | 2025-04-17 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $2.28 | +657.9K | 809.3K | +434% | +$1.50M |
| T | 2025-04-25 | 2025-04-17 | UPXI | Norstrud Andrew James | CFO, Dir | P - Purchase | $2.28 | +43.9K | 59.1K | +287% | +$100.0K |
| T | 2025-04-25 | 2025-04-17 | UPXI | Norstrud Andrew James | CFO, Dir | A - Grant | $0.00 | +100.0K | 159.1K | +169% | $0 |
| M | 2024-03-18 | 2024-03-11+ | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $0.5753 | +77.8K | 2.88M | +3% | +$44.7K |
| 2024-03-06 | 2024-03-05 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $0.7 | +103.0K | 2.86M | +4% | +$72.1K | |
| M | 2023-12-20 | 2023-12-14+ | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $0.9554 | +12.9K | 2.77M | +0.5% | +$12.3K |
| 2023-12-07 | 2023-12-07 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $0.94 | +90.0K | 2.75M | +3% | +$84.6K | |
| M | 2023-12-06 | 2023-12-04+ | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $0.7569 | +53.5K | 2.65M | +2% | +$40.5K |
| M | 2023-07-07 | 2023-06-22+ | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $2.36 | +79.9K | 2.62M | +3% | +$188.9K |
| 2023-05-23 | 2023-05-22 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $3.41 | +22.8K | 2.61M | +0.9% | +$77.7K | |
| M | 2023-03-20 | 2023-03-15+ | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $4.41 | +13.0K | 2.59M | +0.5% | +$57.3K |
| M | 2023-01-11 | 2022-12-14+ | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $3.69 | +17.3K | 2.57M | +0.7% | +$63.9K |
| 2022-12-13 | 2022-12-09 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $4.11 | +12.0K | 2.56M | +0.5% | +$49.3K | |
| 2022-12-05 | 2022-12-01 | UPXI | MARSHALL ALLAN | CEO, Dir, 10% | P - Purchase | $3.96 | +18.5K | 2.55M | +0.7% | +$73.2K | |
| I | 2022-04-01 | 2022-03-30 | UPXI | Salkind Gene | Dir, 10% | P - Purchase | $4.00 | +125.0K | 125.0K | New | +$500.0K |
Purchase Sale Sale after option exercise All abbreviations